Skip to main content

Advertisement

SpringerLink
Log in

Cost-Effectiveness of Screening Helicobacter pylori for Gastric Cancer Prevention: a Systematic Review

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Globally, prevalence of Helicobacter pylori is around 50%, and it has a directly proportional relationship with gastric cancer. Screening and treatment of Helicobacter pylori could reduce gastric cancer by 35%. Drawing on the scarce resources, it is reasonable to use the most cost-effectiveness Helicobacter pylori screening procedure. The purpose of this study was to evaluate Helicobacter pylori screening techniques and to specify the efficient technique from a cost-effectiveness perspective. This systematic review was conducted via searching electronic databases including Scopus, Embase, PubMed, Web of Science, and Cochrane Reviews. Our search retrieved 904 articles, of which, 606 full-text studies have been selected after duplicate removal. Next, the 25 articles were sorted based on eligibility criteria and quality appraisal; eventually, only eight studies have been included for analysis. We reported the incremental cost-effectiveness ratio (ICER) screening compared to non-screening and different screening strategies. Eight studies were identified and retained for the final analysis. In this study, when screening techniques were compared to no-screening, serology screening techniques showed to be cost-effective. The lowest ICER calculated was US$$1230 cost per life-year gained (LYG) and US$1500 cost per quality-adjusted life-year (QALY). However, determining the optimal strategy compared to other strategies was depended on parameters such as context-specific, type of cost, threshold, and perspective, and also, it influenced by the framework of the cost-effectiveness analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, et al. Screening for gastric cancer in Asia: current evidence and practice. The lancet oncology. 2008;9(3):279–87.

  2. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.

    Article  PubMed  Google Scholar 

  3. Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nat Genet. 2014;46(9):994–1000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150(5):1113–24. e5.

  5. Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020.

  6. Humans IWGotEoCRt. schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog. Risks Hum. 1994;61:177–240.

  7. Pounder R, Ng D. The prevalence of Helicobacter pylori infection in different countries. Alimentary pharmacology & therapeutics Supplement. 1995;9(2):33–9.

    Google Scholar 

  8. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut. 2012;61(5):646–64.

    Article  CAS  PubMed  Google Scholar 

  9. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.

    Article  PubMed  Google Scholar 

  10. Kaur G, Naing NN. Prevalence and ethnic distribution of Helicobacter pylori infection among endoscoped patients in North Eastern Peninsular Malaysia. The Malaysian journal of medical sciences: MJMS. 2003;10(2):66.

    PubMed  PubMed Central  Google Scholar 

  11. Fuccio L, Zagari R, Minardi M, Bazzoli F. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther. 2007;25(2):133–41.

    Article  CAS  PubMed  Google Scholar 

  12. Fashner J, Gitu AC. Diagnosis and treatment of peptic ulcer disease and H. pylori infection. Am Fam Physician. 2015;91(4):236–42.

  13. Talebi Bezmin Abadi A. Diagnosis of Helicobacter pylori using invasive and noninvasive approaches. J Pathog. 2018;2018.

  14. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Organization WH. Table: Threshold values for intervention cost-effectiveness by Region. World Health Organization Available: http://www.who/int/choice/costs/CER_levels/en/index html Accessed. 2013;7.

  16. Clinical If, Review E. Overview of the ICER value assessment framework and update for 2017–2019. 2018.

  17. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes: Oxford university press; 2015.

  18. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. The Lancet. 1996;348(9021):150–4.

    Article  CAS  Google Scholar 

  19. Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer. 2009;124(1):157–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Xie F, Luo N, Lee H-P. Cost effectiveness analysis of population-based serology screening and 13C-urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model. World J Gastroenterol: WJG. 2008a;14(19):3021.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Wong O, Schooling C, Cowling B. Cost-effectiveness of Helicobacter pylori screening and. Hong Kong Med J. 2014;20(6 Suppl 7):S13–5.

    Google Scholar 

  22. Xie F, Luo N, Blackhouse G, Goeree R, Lee H-P. Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. Int J Technol Assess Health Care. 2008b;24(1):87.

    Article  PubMed  Google Scholar 

  23. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med. 1999;159(2):142–8.

    Article  CAS  PubMed  Google Scholar 

  24. Xie F, O’Reilly D, Ferrusi IL, Blackhouse G, Bowen JM, Tarride J-E, et al. Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J Am Coll Radiol. 2009;6(5):317–23.

    Article  PubMed  Google Scholar 

  25. Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity. BMC Infect Dis. 2017;17(1):156.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Areia M, Carvalho R, Cadime AT, Rocha Gonçalves F, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013;18(5):325–37.

    Article  PubMed  Google Scholar 

  27. Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2013;27(6):933–47.

    Article  PubMed  Google Scholar 

  28. Ameri H, Safari H, Yousefi M. Interim value set for the EQ-5D-5L in Iran using the Crosswalk method. Med J Islam Repub Iran. 2020;34:121.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank all the authors who contributed sincerely to the data and documentation provided in this article. This paper was extracted from the master’s thesis of MS, supervised by MY, and supported by Tabriz University of Medical Sciences (Approval ID: IR.TBZMED.REC.1397.756)

Author information

Authors and Affiliations

  1. Department of Health Economics, School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran

    Maryam Sarmasti

  2. Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    Manouchehr Khoshbaten

  3. Department of Health Economics, School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran

    Mahmood Yousefi

  4. Department of Health Economics, School of Management and Medical Informatics, Tabriz Health Services Management Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    Farhad Khalili & Mahmood Yousefi

Authors
  1. Maryam Sarmasti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manouchehr Khoshbaten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Farhad Khalili
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mahmood Yousefi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mahmood Yousefi.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 14 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sarmasti, M., Khoshbaten, M., Khalili, F. et al. Cost-Effectiveness of Screening Helicobacter pylori for Gastric Cancer Prevention: a Systematic Review. J Gastrointest Canc 53, 1093–1103 (2022). https://doi.org/10.1007/s12029-021-00726-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-021-00726-7

Keywords

Search

Navigation